Cargando…
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
BACKGROUND: Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was to identify the factors underpinning such inequalities. METHODS: A national prospective survey was conducted in 11 early-phase cli...
Autores principales: | Charton, E., Baldini, C., Fayet, Y., Schultz, E., Auroy, L., Vallier, E., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Touzeau, C., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.-J., Delord, J.-P., Gomez Roca, C., Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.-C., Massard, C., Besle, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415590/ https://www.ncbi.nlm.nih.gov/pubmed/37536254 http://dx.doi.org/10.1016/j.esmoop.2023.101610 |
Ejemplares similares
-
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
por: Baldini, C., et al.
Publicado: (2022) -
Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
por: Samaille, T., et al.
Publicado: (2021) -
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015) -
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
por: Even, C., et al.
Publicado: (2019) -
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)